LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on the respiratory syncytial virus. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of the respiratory syncytial virus. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
Respiratory syncytial virus: An overview
Respiratory syncytial virus (RSV) is one of the most common diseases that affect children. RSV is one of the human pathogens in infants, young children, and the elderly. It also affects the people with an impaired immune system. Almost all children are exposed to RSV by the age of two. RSV causes common cold in most patients. In unguarded children, RSV can develop to either bronchiolitis or pneumonia or even both with increased chances of notable morbidity or death. Understanding how RSV interacts with its host is crucial to facilitate the development of safe and effective vaccines and therapeutic treatments.
RSV enters the body through the nose, eyes, or mouth and spreads easily through the air. A person can get infected if a person infected with RSV coughs or sneezes near him/her.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Respiratory syncytial virus: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with more than 23% of the pipeline molecules administered through this mode.
Between companies and institutions, companies led the drug development space for the treatment of the respiratory syncytial virus. Some of the key players include ABIVAX, Ablynx, CureVac, Enanta, and Gilead.
Looking for more information? Request your free sample today
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development Landscape
- Drugs under development
4. Drug Development Strategies
- Therapies employed
- Route of administration
- Therapeutic modality
- Mechanism of action
5. Recruitment Strategies
- Geographical coverage
- Recruitment status
- Gender
- Age
6. Key Companies
- Type of players
- Company overview
7. Discontinued and Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
